Progyny, Inc.(PGNY) Stock Research - Grey Stern Research

Progyny, Inc. (PGNY) Stock Analysis

$22.31 (2.15%)

PGNY Financial Performance


Use the table below to view Progyny, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $22.31 -
52 Week Low $13.39 -
52 Week High $38.98 -
Market Cap $1.9 Billion 4/16
Gross Margin 21% 13/16
Profit Margin 4% 5/16
EBITDA margin 5% 8/16
Q3 - 2024 Revenue $298.4 Million 7/16
Q3 - 2024 Earnings $10.5 Million 2/16
Q3 - 2024 Free Cash Flow $0 Million 13/16
Trailing 4 Quarters Revenue $1.2 Billion 7/16
Trailing 4 Quarters Earnings $54.3 Million 2/16
Quarterly Earnings Growth -22% 10/16
Annual Earnings Growth -11% 10/16
Quarterly Revenue Growth 11% 6/16
Annual Revenue Growth 5% 9/16
Cash On Hand $162.3 Million 9/16
Short Term Debt $0 13/16
Long Term Debt $16.4 Million 13/16

Progyny, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Progyny, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 35.07 5/16
PS 1.63 10/16
PB 4.51 4/16
PC 11.74 8/16
Liabilities to Equity 0.44 13/16
ROA 0.09 3/16
ROE 0.13 2/16
Current Ratio 3.28 4/16
Quick Ratio 1.23 3/16
Long Term Debt to Equity 0.04 10/16
Debt to Equity 0.04 12/16
Burn Rate -16.44 13/16
Cash to Cap 0.09 8/16
CCR 13/16
EV to EBITDA 111.46 5/16
EV to Revenue 1.51 11/16

Company Details

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

CEO: Mr. David Schlanger

Website: https://www.progyny.com

Address: 1359 BROADWAY, 2ND FLOOR New York City, NEW YORK

Exchange: NASDAQ Global Select

Industry: Health Information Services

Progyny, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Progyny, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Veeva Systems Inc. VEEV $38.6 Billion
Evolent Health, Inc. EVH $1.1 Billion
Teladoc Health, Inc. TDOC $1.5 Billion
R1 RCM Inc. RCM $6.0 Billion
HealthStream, Inc. HSTM $976.6 Million
Phreesia, Inc. PHR $1.6 Billion
Health Catalyst, Inc. HCAT $323.0 Million
National Research Corporation NRC $322.4 Million
NextGen Healthcare, Inc. NXGN $1.6 Billion
10x Genomics, Inc. TXG $1.2 Billion
GoodRx Holdings, Inc. GDRX $1.7 Billion
Certara, Inc. CERT $1.6 Billion
Agiliti, Inc. AGTI $1.4 Billion
Privia Health Group, Inc. PRVA $2.8 Billion
Definitive Healthcare Corp. DH $334.2 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
PGNY Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 298.4 Million $10.5 Million
Q3 2024 $ 286.6 Million $10.4 Million
Q2 2024 $ 304.1 Million $16.5 Million
Q1 2024 $ 278.1 Million $16.9 Million
Q4 2023 $ 269.9 Million $13.5 Million
Q3 2023 $ 280.9 Million $15.9 Million
Q2 2023 $ 279.4 Million $15.0 Million
Q1 2023 $ 258.4 Million $17.7 Million

View All

PGNY Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $162.3 Million $607.1 Million $16.4 Million $422.1 Million
Q3 2024 $91.5 Million $660.0 Million $16.6 Million $434.9 Million
Q2 2024 $95.0 Million $698.6 Million $19.9 Million $456.2 Million
Q1 2024 $115.0 Million $794.3 Million $19.3 Million $571.6 Million
Q4 2023 $97.3 Million $756.6 Million $17.2 Million $553.4 Million
Q3 2023 $158.1 Million $726.5 Million $17.7 Million $515.4 Million
Q2 2023 $170.6 Million $681.5 Million $18.1 Million $469.5 Million
Q1 2023 $155.3 Million $649.7 Million $18.5 Million $424.4 Million

View All

PGNY Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $42.7 Million -$1.8 Million -$3.5 Million
Q2 2024 $55.8 Million -$866,000 -$20.0 Million
Q1 2024 $24.9 Million -$850,000 $17.7 Million
Q4 2023 $37.0 Million -$681,000 -$60.8 Million
Q3 2023 $52.8 Million $0 $52.8 Million
Q2 2023 $75.3 Million -$759,000 $15.3 Million
Q1 2023 $19.7 Million -$1.3 Million $35.2 Million
Q4 2022 $50.8 Million -$721,000 $47.6 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions